Electromedical T Financials
This page shows Electromedical T (EMED) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2023 annual data. Scores normalized against common benchmarks. How we calculate these scores
Electromedical T has an operating margin of -153.1%, meaning the company retains $-153 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -139.5% the prior year.
Electromedical T's revenue surged 17.3% year-over-year to $1.3M, reflecting rapid business expansion. This strong growth earns a score of 78/100.
Electromedical T's current ratio of 0.13 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.
While Electromedical T generated -$1.4M in operating cash flow, capex of $150K consumed most of it, leaving -$1.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Electromedical T passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Electromedical T generates $0.54 in operating cash flow (-$1.4M OCF vs -$2.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Electromedical T earns $-2.3 in operating income for every $1 of interest expense (-$2.1M vs $893K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Electromedical T generated $1.3M in revenue in fiscal year 2023. This represents an increase of 17.3% from the prior year.
Electromedical T's EBITDA was -$2.1M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 30.3% from the prior year.
Electromedical T generated -$1.6M in free cash flow in fiscal year 2023, representing cash available after capex.
Electromedical T reported -$2.6M in net income in fiscal year 2023. This represents an increase of 23.9% from the prior year.
Electromedical T earned $0.00 per diluted share (EPS) in fiscal year 2023. This represents an increase of 100.0% from the prior year.
Electromedical T held $88K in cash against $150K in long-term debt as of fiscal year 2023.
Electromedical T had 463M shares outstanding in fiscal year 2023. This represents an increase of 144.0% from the prior year.
Electromedical T's gross margin was 77.5% in fiscal year 2023, indicating the percentage of revenue retained after direct costs. This is up 0.2 percentage points from the prior year.
Electromedical T's operating margin was -153.1% in fiscal year 2023, reflecting core business profitability. This is down 13.6 percentage points from the prior year.
Electromedical T's net profit margin was -195.8% in fiscal year 2023, showing the share of revenue converted to profit. This is up 105.8 percentage points from the prior year.
Electromedical T invested $231K in research and development in fiscal year 2023. This represents an increase of 150.7% from the prior year.
Electromedical T invested $150K in capex in fiscal year 2023, funding long-term assets and infrastructure.
EMED Income Statement
| Metric | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $43K-82.1% | $238K-18.1% | $290K-17.4% | $352K+19.2% | $295K-22.1% | $379K-10.5% | $423K+51.4% | $280K |
| Cost of Revenue | $12K-81.5% | $64K-11.6% | $73K-9.7% | $81K+29.0% | $63K-28.7% | $88K-2.8% | $90K+55.5% | $58K |
| Gross Profit | $31K-82.3% | $173K-20.3% | $217K-19.8% | $271K+16.6% | $232K-20.1% | $291K-12.6% | $333K+50.3% | $222K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $412K-3.2% | $425K+14.2% | $372K-24.6% | $494K-13.9% | $574K-63.0% | $1.6M+163.0% | $590K+5.6% | $559K |
| Operating Income | -$381K-51.3% | -$252K-62.6% | -$155K+30.5% | -$223K+34.7% | -$341K+72.9% | -$1.3M-390.2% | -$257K+23.7% | -$337K |
| Interest Expense | $55K-5.8% | $58K-1.7% | $59K+1.7% | $58K-79.5% | $284K-26.7% | $388K+38.3% | $281K+74.8% | $161K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$725K-413.4% | $231K+127.7% | -$836K-139.9% | -$349K+76.1% | -$1.5M-220.1% | -$456K+45.1% | -$830K+13.3% | -$958K |
| EPS (Diluted) | N/A | $0.00+100.0% | $-0.00-200.0% | $0.00 | $0.00+100.0% | $-0.00+80.0% | $-0.010.0% | $-0.01 |
EMED Balance Sheet
| Metric | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $569K-14.5% | $665K-5.9% | $707K-5.5% | $748K-27.5% | $1.0M-34.3% | $1.6M+16.1% | $1.4M-3.7% | $1.4M |
| Current Assets | $305K-21.5% | $389K-7.2% | $419K-6.6% | $449K-49.1% | $882K-43.8% | $1.6M+142.5% | $648K-6.7% | $694K |
| Cash & Equivalents | $35K-70.2% | $117K+48.3% | $79K-10.1% | $88K-78.9% | $416K-66.3% | $1.2M+235.2% | $368K-19.7% | $459K |
| Inventory | $24K-23.4% | $32K-32.0% | $47K-32.0% | $69K-39.4% | $113K-29.1% | $160K+157.3% | $62K-47.2% | $118K |
| Accounts Receivable | $7K+67.2% | $4K+23.9% | $4K-20.4% | $4K-82.9% | $26K+342.6% | $6K-38.3% | $9K-43.4% | $17K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.6M+12.5% | $4.1M-7.5% | $4.4M+21.4% | $3.6M+9.3% | $3.3M+27.3% | $2.6M-27.2% | $3.6M+13.8% | $3.1M |
| Current Liabilities | $4.4M+13.7% | $3.8M-7.6% | $4.1M+23.5% | $3.4M+6.4% | $3.2M+29.1% | $2.4M-16.5% | $2.9M+18.0% | $2.5M |
| Long-Term Debt | N/A | N/A | N/A | $150K | N/A | N/A | $672K | N/A |
| Total Equity | -$4.0M-17.8% | -$3.4M+7.8% | -$3.7M-28.4% | -$2.9M-25.9% | -$2.3M-120.9% | -$1.0M+53.5% | -$2.2M-27.9% | -$1.7M |
| Retained Earnings | -$28.8M-2.6% | -$28.1M+0.8% | -$28.3M-3.0% | -$27.5M-2.7% | -$26.7M-5.8% | -$25.3M-1.8% | -$24.8M-3.6% | -$24.0M |
EMED Cash Flow Statement
| Metric | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$31K-128.3% | $109K+168.8% | -$158K-210.8% | -$51K+92.0% | -$636K-40.5% | -$453K-1267.8% | -$33K+89.8% | -$324K |
| Capital Expenditures | N/A | N/A | N/A | $0 | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | -$51K | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | $0+100.0% | -$150K-107.9% | $1.9M | N/A | N/A |
| Financing Cash Flow | -$51K+27.6% | -$71K-147.4% | $150K+85328.6% | $175+100.5% | -$33K+94.2% | -$575K-902.3% | -$57K-108.0% | $718K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EMED Financial Ratios
| Metric | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.1%-0.8pp | 72.9%-2.0pp | 74.9%-2.2pp | 77.1%-1.7pp | 78.8%+2.0pp | 76.8%-1.8pp | 78.7%-0.6pp | 79.3% |
| Operating Margin | -896.0%-790.0pp | -106.0%-52.6pp | -53.4%+10.1pp | -63.4%+52.3pp | -115.8%+217.4pp | -333.2%-272.4pp | -60.8%+59.9pp | -120.7% |
| Net Margin | -1704.0%-1801.3pp | 97.3%+385.4pp | -288.1%-189.0pp | -99.2%+395.8pp | -494.9%-374.5pp | -120.4%+75.7pp | -196.2%+146.5pp | -342.7% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -127.4%-162.2pp | 34.8%+153.1pp | -118.3%-71.7pp | -46.6%+94.9pp | -141.5%-112.5pp | -29.0%+32.3pp | -61.3%+6.8pp | -68.2% |
| Current Ratio | 0.07-0.0 | 0.100.0 | 0.10-0.0 | 0.13-0.1 | 0.28-0.4 | 0.64+0.4 | 0.22-0.1 | 0.28 |
| Debt-to-Equity | -1.14+0.1 | -1.200.0 | -1.19-1.1 | -0.05+1.4 | -1.45+1.1 | -2.52-2.2 | -0.30+1.5 | -1.81 |
| FCF Margin | N/A | N/A | N/A | -14.5% | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$2.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.13), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Electromedical T's annual revenue?
Electromedical T (EMED) reported $1.3M in total revenue for fiscal year 2023. This represents a 17.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Electromedical T's revenue growing?
Electromedical T (EMED) revenue grew by 17.3% year-over-year, from $1.1M to $1.3M in fiscal year 2023.
Is Electromedical T profitable?
No, Electromedical T (EMED) reported a net income of -$2.6M in fiscal year 2023, with a net profit margin of -195.8%.
What is Electromedical T's earnings per share (EPS)?
Electromedical T (EMED) reported diluted earnings per share of $0.00 for fiscal year 2023. This represents a 100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Electromedical T's EBITDA?
Electromedical T (EMED) had EBITDA of -$2.1M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Electromedical T have?
As of fiscal year 2023, Electromedical T (EMED) had $88K in cash and equivalents against $150K in long-term debt.
What is Electromedical T's gross margin?
Electromedical T (EMED) had a gross margin of 77.5% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
What is Electromedical T's operating margin?
Electromedical T (EMED) had an operating margin of -153.1% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.
What is Electromedical T's net profit margin?
Electromedical T (EMED) had a net profit margin of -195.8% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.
What is Electromedical T's free cash flow?
Electromedical T (EMED) generated -$1.6M in free cash flow during fiscal year 2023. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Electromedical T's operating cash flow?
Electromedical T (EMED) generated -$1.4M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Electromedical T's total assets?
Electromedical T (EMED) had $748K in total assets as of fiscal year 2023, including both current and long-term assets.
What are Electromedical T's capital expenditures?
Electromedical T (EMED) invested $150K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does Electromedical T spend on research and development?
Electromedical T (EMED) invested $231K in research and development during fiscal year 2023.
How many shares does Electromedical T have outstanding?
Electromedical T (EMED) had 463M shares outstanding as of fiscal year 2023.
What is Electromedical T's current ratio?
Electromedical T (EMED) had a current ratio of 0.13 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Electromedical T's debt-to-equity ratio?
Electromedical T (EMED) had a debt-to-equity ratio of -0.05 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Electromedical T's return on assets (ROA)?
Electromedical T (EMED) had a return on assets of -352.9% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Electromedical T's cash runway?
Based on fiscal year 2023 data, Electromedical T (EMED) had $88K in cash against an annual operating cash burn of $1.4M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Electromedical T's debt-to-equity ratio negative or unusual?
Electromedical T (EMED) has negative shareholder equity of -$2.9M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Electromedical T's Piotroski F-Score?
Electromedical T (EMED) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Electromedical T's earnings high quality?
Electromedical T (EMED) has an earnings quality ratio of 0.54x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Electromedical T cover its interest payments?
Electromedical T (EMED) has an interest coverage ratio of -2.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Electromedical T?
Electromedical T (EMED) scores 20 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.